Recent advances in nanoparticle carriers for coordination complexes

Current Topics in Medicinal Chemistry

Volumn 15, Issue 4, 2015, Pages 287-297

  Sato, Mariana Rillo ^a   Da Silva, Patricia Bento ^a   De Souza, Rodrigo Alves ^a   Dos Santos, Karen Cristina ^a   Chorilli, Marlus ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Biological activity; Coordination compound; Drug delivery systems; Metallic complex; Nanosystems; Nanotechnology

Indexed keywords

CHLOROPHYLL; COORDINATION COMPOUND; CYANOCOBALAMIN; CYCLODEXTRIN; GOLD NANOPARTICLE; HEMOGLOBIN; LIGAND; MAGNETIC NANOPARTICLE; NANOPARTICLE; NANOPARTICLE CARRIER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER;

ARTICLE; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; LIPID MEMBRANE; MICROEMULSION; NANOTECHNOLOGY; NONHUMAN; CHEMISTRY; HUMAN;

COORDINATION COMPLEXES; DRUG CARRIERS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84939792392     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150108145614     Document Type: Article

References (126)

1. Rayner-Canham, G.; Overton, T. Descriptive Inorganic Chemistry; W.H. Freeman and Company: New York, NY, 2010, pp. 500-501.
2. Nobelprize.org. On the constitution and configuration of higherorder compounds. http://www.nobelprize.org/nobel_prizes/ chemistry/ laureates/1913/werner-lecture.pdf[Accessed on June 2014].
3. Nobelprize.org. The Nobel Prize in Chemistry 1913. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1913/ [Accessed on June 2014].
4. Miessler, G.L.; Tarr, D.A. Inorganic Chemistry, 3rd ed.; Pearson Prentice Hall: Upper Saddle River, NJ, 2004, pp. 323-333.
5. Atkins, P.; Overton, T.; Rourke, J.; Weller, M.; Armstrong, F. Shriver & Atkins’ Inorganic Chemistry, 5th ed.; Oxford University Press: New York, NY, 2010, pp. 204-208.
6. Huheey, J.E.; Keiter, E.A.; Keiter, R.L. Inorganic Chemistry: Principles of Structure and Reactivity, 4th ed.; Harper Collins College Publishers: New York, NY, 1993, pp. 513-531.
7. Crabb, E.; Moore, E., Eds. Metals and Life; RSC Publishing: Cambridge, UK, 2010.
8. Ferreira, H.S.; Rangel, M.C. Nanotecnologia: aspectos gerais e potencial de aplicação em catálise. Quim. Nova, 2009, 32(7), 1860-1870.
9. Rossi-Bergmann, B.A. Nanotecnologia: da saúde para além do determinismo tecnológico. Cienc. Cult., 2008, 60(2), 54-57.
10. Faria-Tischer, P.C.S.; Tischer, C.A. Nanobiotechnology, biomaterials and biological application of nanostructures. Biochem. Biotechnol. Rep., 2012, 1(1), 32-53.
11. de Melo, C.P.; Pimenta, M. Nanociências e Nanotecnologia. Parc. Estrat., [Online] 2004, 18, 9-22. http://www.cgee.org.br/ parcerias/p18.php (Accessed June 18, 2014).
12. ABDI-Agência Brasileira de Desenvolvimento Industrial: panorama nanotecnologia. http://www.abdi.com.br/Estudo/Cartilha%20nanotecnologia.pdf (Accessed June 18, 2014).
13. Dimer, F.A.; Friedrich, R.B.; Beck, R.C.R.; Guterres, S.S. Impactos da nanotecnologia na saúde: produção de medicamentos. Quim. Nova, 2013, 36(10), 1520-1526.
14. Brochado, P.M.D.S.C. Nanotecnologia e a sua Aplicação á Terapêutica Oncológica. PhD Thesis, Universidade Lusófona de Humanidades e Tecnologias: Lisboa, December 2013.
15. Garcia, F.M. Avanços na nanomedicina: a nova fronteira da medicina-artigo de atualização. Rev. Ciênc. Saúde, 2014, 12(1), 110-117.
16. Marques, I.R. Novos Sistemas Terapêuticos Nanotecnológicos; Universidade Fernando Pessoa: Porto, 2008/2009.
17. Mei, L.; Zhang, Z.; Zhao, L.; Huang, L.; Yang, X.L.; Tang, J.; Feng, S. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv. Drug Delivery Rev., 2013, 65(6), 880-890.
18. Pimentel, L.F.; Junior, A.T.J.; Mosqueira, V.C.F. Nanotecnologia farmacêutica aplicada ao tratamento da malária. Rev. Bras. Cienc. Farm., 2007, 43(4), 503-514.
19. Marques, I.; Lopes, C.M.; Souto, E.B. Novos sistemas terapêuticos nanotecnológicos. Rev. Facul. Ciências da Saúde, 2009, 6(2009), 60-68.
20. Farokhzad, O.C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano., 2009, 3(1), 16-20.
21. Ramos, B.G.Z.; Pasa, T.B.C. O desenvolvimento da nanotecnologia: cenário mundial e nacional de investimentos. Rev. Bras. Farm., 2008, 89(2), 95-101.
22. Gonçalves, J.C. Nanotecnologia Aplicada à Pele. PhD Thesis, Universidade Lusófona de Humanidades e Tecnologias: Lisboa, December 2014.
23. Daudt, R.M.; Emanuelli, J.; Kulkamp-Guerreiro, I.C.; Pohlmann, A.R.; Guterres, S.S. A nanotecnologia como estratégia para o desenvolvimento de cosméticos. Ci. e Cult., 2013, 65(3), 28-31.
24. Ghosh, P.K.; Murthy, R.S.R. Microemulsions: a potential drug delivery system. Curr. Drug Deliv., 2006, 3(2), 167-180.
25. Tiwari, G.; Tiwari, R.; Rai, A.K. Cyclodextrin in delivery systems: aplications. J. Pharm. Bioallied. Sci. 2010, 2(2): 72-79.
26. Dimer, F.A.; Friedrich, R.B.; Beck, R.C.R.; Guterres, S.S.; Pohlmann, A.R. Impacto da nanotecnologia na saúde: produção de medicamentos. Quim. Nova, 2013, 36(10), 1520-1526.
27. Yadav, N.; Khatak, S.; Sara, U.V.S. Solid lipid nanoparticles-a review. Int. J. App. Pharm., 2013; 5(2), 8-18.
28. Hu, F-Q.; Jiang, S-P.; Du, Y-Z.; Yuan, H.; Ye, Y-Q.; Zeng, S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int. J. Pharm., 2006, 314(1), 83-89.
29. Zhang, L.; Gu, F.X.; Chan, J.M.; Wang, A.Z.; Langer, R.S.; Farokhzad, O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83(5), 760-769.
30. Calixto, G.; Bernegossi, J.; Fonseca-Santos, B.; Chorilli, M. Nanotechnology-based drug delivery systems. Int. J. Nanomedicine, 2014, 9, 3719-3735.
31. Schulman, J.H.; Stoeckenius, W.; Prince, L.M. Mechanism of formation and structure of micro emulsions by electron microscopy. J. Phys. Chem., 1959, 63(10), 1677-1959.
32. Benita, S. Submicron emulsion in drug targeting and delivery, Harwood Academic: Amsterdam, 1998.
33. Bonifacio, B.V.; Silva, P.B.; Ramos, M.A.S.; Negri, K.M.S.; Bauab, T.M.; Chorilli, M. Nanotechnology-based drug delivery systems and herbal medicines: a review. Int. J. Nanomedicine, 2014, 9, 1-15.
34. Silva, P.B.; Ramos, M.A.S.; Bonifacio, B.V.; Negri, K.M.S.; Sato, M.R.; Bauab, T.M.; Chorilli, M. Nanotechnological strategies for vaginal administration of drugs-a review. J. Biomed. Nanotechnol., 2014, 10, 2218-2243.
35. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv. Drug Delivery Rev., 2002, 54(1), S77-S98.
36. Tenjarla S. Microemulsions: an overview and pharmaceutical applications. Crit. Rev. Ther. Drug Carrier Syst., 1999, 16(5):461-521.
37. Anton, N.; Vandamme, T.F. The universality of low-energy nanoemulsification. Int. J. Pharm., 2009, 377(1-2), 142-147.
38. Lee, S.J.; McClements, D.J. Fabrication of protein-stabilized nanoemulsions using a combined homogenization and amphiphilic solvent dissolution/evaporation approach. Food Hydrocolloid., 2010, 24(6-7), 560-569.
39. McClements, D.J. Crystals and crystallization in oil-in-water emulsions: implications for emulsion-based delivery systems. Adv. Colloid Interface Sci., 2012, 174, 1-30.
40. Freitas, E.S.; Da Silva, P.B.; Chorilli, M.; Batista, A.A.; Lopes, E.O.; Da Silva, M.M.; Leite, C.Q.F.; Pavan, F.R. Nanostructured lipid systems as a strategy to improve the in vitro cytotoxicity of ruthenium(II) compounds. Molecules, 2014, 19, 5999-6008.
41. Silva, P.B. Síntese, caracterização e investigação das atividades biológicas de complexos de cobre(II) contendo moléculas bioativas e ligantes nitrogenados. PhD Thesis, Universidade Estadual Paulista-Instituto de Química: Araraquara, September 2012.
42. Szejtli, J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev., 1998, 98(5), 1743−1753.
43. Schardinger, F. Uber thermophile bakterien aus verschiedenen speisen und milch, sowie uber einige umsetzungsprodukte derselben in kohlenhydrathaltigen nahrlosungen, darunter krystallisierte Genussm., 1903, 6(16), 865-880.
44. Astray, G.; Gonzalez-Barreiro, C.; Mejuto, J.C.; Rial-Otero, R.; Simal-Gándara, J. A review on the use of cyclodextrins in foods. Food Hydrocolloid., 2009, 23(7), 1631-1640.
45. Rolling, P.; Lamers, M.; Staudt, C. Cross-linked membranes based on acrylated cyclodextrins and polyethylene glycol dimethacrylates for aromatic/aliphatic separation. J. Membr. Sci., 2010, 362(1-2), 154-163.
46. Davis, M.E.; Brewster, M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discovery., 2004, 3(12), 1023-1035.
47. Sá-Barreto, C.L.; Cunha-Filho, M.S.S. Ciclodextrina: importante excipiente farmacêutico funcional. Lat. Am. J. Pharm., 2008, 27(4), 629-636.
48. Del Valle, E.M.M. Cyclodextrins and their uses: a review. Process. Biochem., 2004, 39(9), 1033-1046.
49. Hamoudi, M.C.; Bochot, A. Oil-cyclodextrin based beads for oral delivery of poorly-soluble drugs. Curr. Top. Med. Chem., 2014, 14(4), 510-517.
50. Saltão, R.; Veiga, F. Ciclodextrinas em novos sistemas terapêuticos. Rev. Bras. Ciênc. Farm., 2001, 37(1), 1-17.
51. Cunha-Filho, M.S.S.; Sá-Barreto, L.C.L. Utilização de ciclodextrinas na formação de complexos de inclusão de interesse farmacêutico. Rev. Ciênc. Farm. Básica Apl., 2007, 28(1), 1-9.
52. Lyra, M.A.M.; Alves, L.D.S.; Fontes, D.A.F.; Soares-Sobrinho, J.L.; Rolim-Neto, P.J. Ferramentas analíticas aplicadas à caracterização de complexos de inclusão fármaco-ciclodextrina. Rev. Ciênc. Farm. Básica Apl., 2010, 31(2), 117-124.
53. Redenti, L.E.; Szenti, L.; Szejtli, J. Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J. Pharm. Sci., 2000, 89(1), 1-8.
54. Irie, T.; Uekama, K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci., 1997, 86(2), 147-162.
55. Matsumoto, K.; Noguchi, Y.; Yoshida, N. Synthesis and antitumor activity of platinum(II) complexes of amino-cyclodextrin. Inorg. Chim. Acta., 1998, 272, 162-167.
56. Hamasaki, K.; Ikeda, H.; Nakamura, A.; Ueno, A.; Toda, F.; Suzuki, I.; Osa, T. Fluorescent sensors of molecular recognition. Modified cyclodextrins capable of exhibiting guest-responsive twisted intramolecular charge transfer fluorescence. J. Am. Chem. Soc., 1993, 115(12), 5035-5040.
57. Bonomo, R.P.; Cucinotta, V.; Allessandro, F.D.; Impellizzeri, G.; Maccarrone, G.; Vecchio, G.; Rizzarelli, E. Conformational features and coordination properties of functionalized cyclodextrins. Formation, stability, and structure of proton and copper(II) complexes of histamine-bearing.beta.-cyclodextrin in aqueous solution. lnorg. Chem., 1991, 30(13), 2708-2713.
58. Beeson, J.C.; Czarnik, A.W. Synthesis and transacylating reactivity of-β-cyclodextrin ethylenediamines. Bioorg. Med. Chem., 1994, 2(4), 297-303.
59. Quintanar-Guerreiro, D.; Alleman, E.; Doelker, E.; Fessi, H. Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique. Pharm. Res., 1998, 15(7), 1056-1063.
60. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudziski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 70(1-2), 1-20.
61. Fessi, H.; Puisieux, F.; Devissaguet, J.P.H.; Ammoury, N.; Benita, S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Intern. Jour. Pharmac., 1989, 55(1), R1-R4.
62. Mattheolabakis, G.; Ribas, B.; Constantinides, P. Nanodelivery strategies in câncer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine, 2012, 7(10), 1577-1590.
63. Gonçalves, A.S.; Macedo, A.S.; Souto, E.B. Therapeutic nanosystems for oncology nanomedicine. Clin. Transl. Oncol., 2012, 14(12), 883-890.
64. Wang, Y.; Yongquan, W.; Fuyou, L.; Daoyong, C. Folic acidmodified iridium(III) coordination polymeric nanoparticles facilitating intracellular release of a phosphorescent residue capable of nuclear entry. Inorg. Chem. Commun., 2014, 40, 143-147.
65. Rieter, W.J.; Pott, K.M.; Taylor, K.M. L.; Lin, W. Nanoscale Coordination Polymers for Platinum-Based Anticancer Drug Delivery. J. Am. Chem. Soc., 2008, 130(35), 11584-11585.
66. Wang, K.; Ma, X.; Shao, D.; Geng, Z.; Zhang, Z ; Wang, Z. Coordination-Induced Assembly of Coordination Polymer Submicrospheres: Promising Antibacterial and in vitro Anticancer Activities. Cryst. Growth Des., 2012, 12(7), 3786-3791.
67. Elhusseiny, A.F.; Hassan, H.H.A.M. Antimicrobial and antitumor activity of platinum and palladium complexes of novel spherical aramides nanoparticles containing flexibilizing linkages: Structureproperty relationship. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2013,103, 232-245.
68. Kreuter, J. Nanoparticles-a historical perspective. Int. J. Pharm., 2007, 331(1), 1-10.
69. Severino, P.; Andreani, T.; Macedo, A.S.; Fangueiro, J.F.; Santana, M.H.A.; Silva, A.M.; Souto, E.B. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J. Drug. Deliv., 2012, 2012, 1-10.
70. ®). Int. J. Cosmet. Sci., 2008, 30(3), 157-165.
71. Uner, M. Preparation, characterization and physicochemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie, 2006, 61(5), 375-386.
72. Saupe, A.; Wissing, S.A.; Lenk, A.; Schmidt, C.; Muller, R.H. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)-structural investigations on two different carrier systems. Bio-Med. Mater. Eng., 2005, 15(5), 393-402.
73. Muller, R.H.; Radtke, M.; Wissing, S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug. Deliv. Rev., 2002, 54(1), 131-155.
74. Wissing, S.A.; Kayser, O.; Muller, R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev., 2004, 56(9), 1257-1272.
75. Fangueiro, J.F.P. Desenvolvimento de nanopartículas lipídicas mucoadesivas. PhD Thesis, Universidade Fernando Pessoa: Porto, December 2012.
76. Marcato, P.D. Preparação, caracterização e aplicações em fármacos e cosméticos de nanopartículas lipídicas sólidas. R. E. F., 2009, 6(2), 1-37.
77. Das, S.; Ng, W.K.; Tan, R.B.H. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazoleloaded SLNs and NLCs? Eur. J. Pharm. Sci., 2012, 47(1), 139-151.
78. Han, F.; Li, S.; Yin, R.; Liu, H.; Xu, L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf. A., 2008, 315(1-3), 210-216.
79. Yang, Y.; Corrona, A.; Schubert, B.; Reeder, R.; Henson, M.A. The effect of oil type on the aggregation stability of nanostrtuctured lipid carrier. J. Colloid Interface Sci., 2014, 418, 261-272.
80. Singlal, G.B.; Patel, R.P.; Prajapati, B.G.; Patel, N.A. Solid lipid nanoparticles and nano lipid carriers: as novel soli lipid based drug carrier. IRJP., 2011, 2(2), 40-52.
81. Marquele-Oliveira, F.; Santana, D.C.A.; Taveira, S.F.; Vermeulen, D.M.; Oliveira, A.R.M.; Silva, R.S.; Lopez, R.F.V. Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: improvement in skin stability and in nitric oxide release by visible light irradiation. J. Pharm. Biomed. Anal., 2010, 53(4), 843-851.
82. Sekhon, B.S.; Kamboj, S.R. Inorganic nanomedicine-Part 1. Nanomedicine, 2010, 6(4), 516-522.
83. Sekhon, B.S.; Kamboj, S.R. Inorganic nanomedicine-Part 2. Nanomedicine, 2010, 6(5), 612-618.
84. Teli, M.K.; Mutalik, S.; Rajanikant, G.K. Nanotechnology and nanomedicine: going small means aiming big. Curr. Pharm. Des., 2010, 16(16), 1882-1892.
85. Bhattacharyya, S.; Kudgus, R.A.; Bhattacharya, R.; Mukherjee, P. Inorganic nanoparticles in cancer therapy. Pharm. Res., 2011, 28(2), 237-259.
86. Chen, B.; Wu, W.; Wang, X. Magnetic iron oxide nanoparticles for tumor-targeted therapy. Curr. Cancer Drug Targets, 2011, 11(2), 184-189.
87. Arvizo, R.R.; Bhattacharyya, S.; Kudgus, R.; Giri, K.; Bhattacharya, R.; Mukherjee, P. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem. Soc. Rev., 2012, 41(7), 2943-2970.
88. Parveen, S.; Misra, R.; Sahoo, S.K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine, 2012, 8(2), 147-166.
89. Bao, G.; Mitragotri, S.; Tong, S. Multifunctional nanoparticles for drug delivery and molecular imaging. Annu. Rev. Biomed. Eng., 2013, 15(2013), 253-282.
90. Ramsden, J.J. Nanotechnology: an introduction; Elsevier: Oxford, UK, 2011.
91. Bogart, L.K.; Pourroy, G.; Murphy, C.J.; Puntes, V.; Pellegrino, T.; Rosenblum, D.; Peer, D.; Lévy, R. Nanoparticles for imaging, sensing, and therapeutic Intervention. ACS Nano, 2014, 8(4), 3107-3122.
92. Janib, S.M.; Moses, A.S.; MacKay, J.A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev., 2010; 62(11), 1052-1063.
93. Yoo, D.; Lee, J-H.; Shin, T-H.; Cheon, J. Theranostic magnetic nanoparticles. Acc Chem. Res., 2011, 44(10), 863-874.
94. Clemente-Casares, X.; Santamaria, P. Nanomedicine in autoimmunity. Immunol. Lett., 2014, 158(1-2), 167-174.
95. Branquinho, L.C.; Carrião, M.S.; Costa, A.S.; Zufelato, N.; Sousa, M.H.; Miotto, R.; Ivkov, R.; Bakuzis, A.F. Effect of magnetic dipolar interactions on nanoparticle heating efficiency: Implications for cancer hyperthermia. Sci. Rep., 2013, 3(2887), 1-10.
96. Xu, C.; Sun, S. New forms of superparamagnetic nanoparticles for biomedical applications. Adv. Drug Deliv. Rev., 2013, 65(5), 732-743.
97. 4Nanoparticles for Targeted Delivery and Controlled Release of Cisplatin. J. Am. Chem. Soc., 2009, 131(30), 10637-10644.
98. Wang, X.; Guo, Z. Targeting and delivery of platinum-based anticancer drugs. Chem. Soc. Rev., 2013, 42(1), 202-224.
99. Maldonado, C.R.; Salassa, L.; Gomez-Blanco, N.; Mareque-Rivas, J.C. Nano-functionalization of metal complexes for molecular imaging and anticancer therapy. Coord. Chem. Rev., 2013, 257(19-20), 2668-2688.
100. Chen, X.; Wu, Y.; Dong, H.; Zhang, C.-Y.; Zhang, Y. Platinumbased agents for individualized cancer treatment. Curr. Molec. Med., 2013, 13(10), 1603-1612.
101. Oberoi, H.S.; Nukolova, N.V.; Kabanov, A.V.; Bronich, T.K. Nanocarriers for delivery of platinum anticancer drugs. Adv. Drug Deliv. Rev., 2013, 65(13-14), 1667-1685.
102. Xue, X.; Hall, M.D.; Zhang, Q.; Wang, P.C.; Gottesman, M.M.; Liang, X-J. Nanoscale drug delivery platforms overcome platinumbased resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano, 2013, 7(12), 10452-10464.
103. Liu, Z.; Li, B.; Wang, B.; Yang, Z.; Wang, Q.; Li, T.; Qin, D.; Li, Y.; Wang, M.; Yan, M. Magnetic nanoparticles modified with DTPA-AMC-rare earth for fluorescent and magnetic resonance dual mode imaging. Dalton Trans., 2012, 41(28), 8723-8728.
104. II-Bis(dithiocarbamatebisphosphonate) and its conjugation with superparamagnetic iron oxide nanoparticles: in vivo evaluation as dual-modality PET-MRI Agent. Angew. Chem. Int. Ed., 2011, 50(24), 5509-5513.
105. Cheng, K.; Sun, S. Recent advances in syntheses and therapeutic applications of multifunctional porous hollow nanoparticles. Nano Today, 2010, 5(3), 183-196.
106. Boisselier, E.; Astruc, D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev., 2009, 38(6), 1759-1782.
107. Giljohann, D.A.; Seferos, D.S.; Daniel, W.L.; Massich, M.D.; Patel, P.C.; Mirkin, C.A. Gold Nanoparticles for Biology and Medicine. Angew Chem. Int. Ed., 2010, 49(19), 3280-3294.
108. Arvizo, R.; Bhattacharya, R.; Mukherjee, P. Gold nanoparticles: Opportunities and challenges in nanomedicine. Expert Opin. Drug Deliv., 2010, 7(6), 753-763.
109. Lim, Z-Z.J.; Li, J-E.J; Ng, C-T.; Yung, L-Y.L.; Bay, B-H. Gold nanoparticles in cancer therapy. Acta Pharmacol. Sin., 2011, 32(8), 983-990.
110. Dykman, L.; Khlebtsov, N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem. Soc. Rev., 2012, 41(6), 2256-2282.
111. Kumar, A.; Zhang, X.; Liang, X-J. Gold nanoparticles: Emerging paradigm for targeted drug delivery system. Biotechnol. Adv., 2013, 31(5), 593-606.
112. Vigderman, L.; Zubarev, E.R. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv. Drug Deliv. Rev., 2013, 65(5), 663-676.
113. Marchesan, S.; Prato, M. Nanomaterials for (nano)medicine. ACS Med. Chem. Lett., 2013, 4(2), 147-149.
114. Huang, D.; Niu, C.; Li, Z.; Ruan, M.; Wanga, X.; Zeng, G. A sensitive strategy for label-free and time-resolved fluorescence assay of thrombin using Tb-complex and unmodified gold nanoparticles. Analyst, 2012, 137(23), 5607-5613.
115. Cao, R. Jr.; Díaz-García, A.M.; Cao, R. Coordination compounds built on metal surfaces. Coord. Chem. Rev., 2009, 253(9-10), 1262-1275.
116. Dhar, S.; Daniel, W.L.; Giljohann, D.A.; Mirkin, C.A.; Lippard, S.J. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J. Am. Chem. Soc., 2009, 131(41), 4652-14653.
117. Min, Y.; Mao, C.; Xu, D.; Wang, J.; Liu, Y. Gold nanorods for platinum based prodrug delivery. Chem. Commun., 2010, 46(44), 8424-8426.
118. 4Core−Shell Nanoparticles: Toward a Novel Cellular Copper Detoxifying Drug for Wilson’s Disease. Chem. Materials., 2013, 25(23), 4703-4709.
119. Chandrasekhar, S. Liquid Crystals Cambridge University Press, 1992, 84-85.
120. Jan, L.S.; Radiman, S.; Siddig M.A.; Muniandy, S.V.; Hamid, M.A.; Jamali H.D. Preparation of nanoparticles of polystyrene and polyaniline by y-irradiation lyotropic liquid crystal. Coll. Surf. A: Physicochem. Eng. Asp., 2004, 251(1-3), 43-52.
121. Mukherjee, P.K. Isotropic to smectic-A phase transition: A review. J. Mol. Liq., 2014, 190, 99-111.
122. Chorilli, M.; Prestes, P.S.; Rigon, R.B.; Leonardi, G.R.; Chiavacci, L.A.; Scarpa, M.V. Desenvolvimento de sistemas líquido-cristalino empregando silicone fluído de co-polímero glicol e poliéter funcional siloxano. Quím. Nova, 2009, 32(4), 1036-1040.
123. Reynolds, P.A.; Henderson, M.J.; White, J.W. A small angle neutron scattering study of the interface between solidsand oilcontinuous emulsions and oil-based microemulsions. Colloids Surf., A, 2004, 232(1), 55-65.
124. Muir, B.W.; Acharya, D.P.; Kennedy, D.F.; Mulet, X.; Evans, R.A.; Pereira, S.M.; Wark, K.L.; Boyd, B.J.; Nguyen, T. H.; Hinton, T.M.; Waddington, L.J.; Kirby, N.; Wright, D.K.; Wang, H.X.; Egan, G.F.; Moffat, B.A. Metal-free and MRI visible theranostic lyotropic liquid crystal nitroxide-based nanoparticles. Biomaterials, 2012, 33(9), 2723-2733.
125. Bruce, D.W. Calamitics, cubics, and columnars-liquid crystalline complexes of silver(I). Acc. Chem. Res., 2000, 33(12), 831-840.
126. Selivanova, N.M.; Galeeva, A.I.; Gubaydullin, A.; Lobkov, V.S.; Galyametdinov, Y.G. Mesogenic and luminescent properties of liquid crystals containing lyotropic Eu(III) and Tb(III) ions. J. Phys. Chem. B, 2012, 116(2), 735-742.